NASDAQ$NPCE
Neuropace Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Neuropace Inc reported Q2 2025 revenue growth to $23.5 million alongside a net loss of $8.7 million.
NeuroPace reported revenue of $23.5 million for the three months ended June 30, 2025, up 22% year-over-year, driven by increased RNS System unit sales and DIXI Medical product distribution. The company recorded a net loss of $8.7 million and an operating loss of $6.8 million, reflecting continued investments in commercial expansion and R&D. Cash and cash equivalents stood at $22.9 million with total assets of $106.1 million at quarter end.
- Q2 revenue reached $23.5 million, a 22% increase from $19.3 million in Q2 2024, primarily from higher RNS System volumes.
- Gross margin improved to 77.1% from 73.4% year-over-year due to production efficiencies and volume leverage.
- Net loss widened to $8.7 million from $7.5 million, impacted by higher operating expenses and a $0.5 million debt extinguishment loss.
- Company completed follow-on offering and debt refinancing, ending quarter with $62.1 million in cash and short-term investments.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$23.5M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.0%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +0.6% | -1.8% | +0.8% | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro